{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:18:56Z","timestamp":1779085136408,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jgo.2019.08.009","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T08:13:05Z","timestamp":1566893585000},"page":"675-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Terufumi","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Shikama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tsurumaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Sasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jgo.2019.08.009_bb0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00268-015-3356-2","article-title":"The global burden of esophageal cancer: a disability-adjusted life-year approach","volume":"40","author":"Di Pardo","year":"2016","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.jgo.2019.08.009_bb0010","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1007\/s00268-012-1762-2","article-title":"Increased resection rates and survival among patients aged 75 years and older with esophageal cancer: a Dutch nationwide population-based study","volume":"36","author":"Faiz","year":"2012","journal-title":"World J Surg"},{"key":"10.1016\/j.jgo.2019.08.009_bb0015","author":"National Cancer Center in Japan"},{"issue":"1","key":"10.1016\/j.jgo.2019.08.009_bb0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2019.08.009_bb0025","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","article-title":"Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906)","volume":"81","author":"Kato","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.jgo.2019.08.009_bb0030","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Cooper","year":"1999","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.jgo.2019.08.009_bb0035","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jjco\/hyt048","article-title":"Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma","volume":"43","author":"Kato","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2019.08.009_bb0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/COC.0b013e3180ca7c84","article-title":"A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer","volume":"30","author":"Takeuchi","year":"2007","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2019.08.009_bb0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02993858","article-title":"Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293","volume":"13","author":"Einzig","year":"1996","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2019.08.009_bb0050","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1053\/j.seminoncol.2005.04.005","article-title":"Docetaxel in the treatment of esophageal cancer","volume":"32","author":"Rigas","year":"2005","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2019.08.009_bb0055","first-page":"1842","article-title":"Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells","volume":"56","author":"Hennequin","year":"1996","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jgo.2019.08.009_bb0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3727\/0965040041791455","article-title":"Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action","volume":"14","author":"Dunne","year":"2004","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.jgo.2019.08.009_bb0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.1998.16.1.159","article-title":"Phase I study of docetaxel with concomitant thoracic radiation therapy","volume":"16","author":"Mauer","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2019.08.009_bb0070","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/dote.12105","article-title":"Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis","volume":"27","author":"Kushida","year":"2014","journal-title":"Dis Esophagus"},{"issue":"6","key":"10.1016\/j.jgo.2019.08.009_bb0075","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0959-8049(97)10101-0","article-title":"Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I\/II dose escalation trial","volume":"34","author":"Koukourakis","year":"1998","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2019.08.009_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0360-3016(03)01370-1","article-title":"Radiotherapy with concomitant weekly docetaxel for Stages III\/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial","volume":"58","author":"Calais","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.jgo.2019.08.009_bb0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10147-003-0375-z","article-title":"Phase I\/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck","volume":"9","author":"Fujii","year":"2004","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2019.08.009_bb0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12094-007-0032-5","article-title":"Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer","volume":"9","author":"Font","year":"2007","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jgo.2019.08.009_bb0095","series-title":"A phase I study of docetaxel with concurrent radiotherapy in patients with esophageal cancer","author":"Hokamura","year":"2008"},{"issue":"4","key":"10.1016\/j.jgo.2019.08.009_bb0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.adro.2016.07.002","article-title":"Chemoradiation therapy with docetaxel in elderly patients with stage II\/III esophageal cancer: a phase 2 trial","volume":"1","author":"Ohba","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jgo.2019.08.009_bb0105","series-title":"Common toxicity criteria, Version2.0 publish date","year":"1999"},{"key":"10.1016\/j.jgo.2019.08.009_bb0110","series-title":"TNM classification of malignant tumours","author":"Brierley","year":"2017"},{"key":"10.1016\/j.jgo.2019.08.009_bb0115","series-title":"Common terminology criteria for adverse events (CTCAE). Rev","author":"National Cancer Institute (U.S.)","year":"2009"},{"issue":"6","key":"10.1016\/j.jgo.2019.08.009_bb0120","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.jgo.2019.08.009_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"4","key":"10.1016\/j.jgo.2019.08.009_bb0130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","article-title":"Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients","volume":"82","author":"Bouillanne","year":"2005","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.jgo.2019.08.009_bb0135","first-page":"1","article-title":"The geriatric nutritional risk index","volume":"12","author":"Cereda","year":"2009","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"3","key":"10.1016\/j.jgo.2019.08.009_bb0140","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jgo.2019.08.009_bb0145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/jtd.2017.03.105","article-title":"Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients","volume":"9","author":"Wang","year":"2017","journal-title":"J Thorac Dis"},{"issue":"4","key":"10.1016\/j.jgo.2019.08.009_bb0150","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.ijrobp.2005.09.027","article-title":"Prospective trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus","volume":"64","author":"Kawashima","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jgo.2019.08.009_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13014-018-1044-8","article-title":"Clinical outcome of elderly patients (>\/= 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis","volume":"13","author":"Walter","year":"2018","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2019.08.009_bb0160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.adro.2018.02.010","article-title":"Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: a retrospective study","volume":"3","author":"Watanabe","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2019.08.009_bb0165","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s12094-016-1603-0","article-title":"The outcomes of radiotherapy and factors that predict overall survival in elderly patients with esophageal squamous cell carcinoma","volume":"19","author":"Yin","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2019.08.009_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155903","article-title":"The geriatric nutritional risk index predicts survival in elderly esophageal squamous cell carcinoma patients with radiotherapy","volume":"11","author":"Bo","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jgo.2019.08.009_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox060","article-title":"Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis","volume":"30","author":"Song","year":"2017","journal-title":"Dis Esophagus"},{"issue":"10","key":"10.1016\/j.jgo.2019.08.009_bb0180","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/sj.bjc.6604749","article-title":"Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer","volume":"99","author":"Tougeron","year":"2008","journal-title":"Br J Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.jgo.2019.08.009_bb0185","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ejon.2005.09.007","article-title":"The causes and consequences of cancer-associated malnutrition","volume":"9","author":"Van Cutsem","year":"2005","journal-title":"Eur J Oncol Nurs"},{"issue":"4","key":"10.1016\/j.jgo.2019.08.009_bb0190","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.7314\/APJCP.2015.16.4.1463","article-title":"Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution","volume":"16","author":"Li","year":"2015","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819302735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819302735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:52:21Z","timestamp":1761817941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406819302735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1879406819302735"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2019.08.009","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2019.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}